A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
At a glance
- Drugs ELX 02 (Primary)
- Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eloxx Pharmaceuticals
- 08 Nov 2018 According to an Eloxx Pharmaceutical media release, the results have been submitted to a scientific journal for publication.
- 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.
- 13 Feb 2018 Status changed from recruiting to completed.